Scott Wadler

10.7k total citations · 1 hit paper
192 papers, 8.1k citations indexed

About

Scott Wadler is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Scott Wadler has authored 192 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 124 papers in Oncology, 51 papers in Pulmonary and Respiratory Medicine and 50 papers in Molecular Biology. Recurrent topics in Scott Wadler's work include Colorectal Cancer Treatments and Studies (57 papers), Cancer Treatment and Pharmacology (34 papers) and Ovarian cancer diagnosis and treatment (27 papers). Scott Wadler is often cited by papers focused on Colorectal Cancer Treatments and Studies (57 papers), Cancer Treatment and Pharmacology (34 papers) and Ovarian cancer diagnosis and treatment (27 papers). Scott Wadler collaborates with scholars based in United States, Canada and Germany. Scott Wadler's co-authors include Edward L. Schwartz, Della Makower, Maurie Markman, David S. Alberts, Joshua Z. Sickel, Jeffrey M. Fowler, Brian N. Bundy, Linda F. Carson, Al B. Benson and Jonathan J. Beitler and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Scott Wadler

192 papers receiving 7.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group

2001 792 citations Scott Wadler et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Scott Wadler

Since Specialization

Citations

This map shows the geographic impact of Scott Wadler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Wadler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Wadler more than expected).

Fields of papers citing papers by Scott Wadler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Wadler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Wadler. The network helps show where Scott Wadler may publish in the future.

Co-authorship network of co-authors of Scott Wadler

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Wadler. A scholar is included among the top collaborators of Scott Wadler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Wadler. Scott Wadler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Report of a Phase I Evaluation of Dose and Schedule of Interleukin-1 Alpha and Cyclophosphamide in Patients with Advanced Tumors: An Eastern Cooperative Oncology Group Study (PX990) and Review of IL-1-Based Studies of Hematopoietic Reconstitution 2014 ·Journal of Interferon & Cytokine Research ·Janice P. Dutcher, Donna Neuberg, Michael B. Atkins, William Tester, Scott Wadler, James A. Stewart, Abraham Chachoua, Lynn M. Schuchter	3
2	Molecular Targeting in Oncology 2007 ·Humana Press eBooks ·Howard L. Kaufman, Scott Wadler, Karen H. Antman	13
3	In vivo synergy between oncolytic reovirus and gemcitibane in ras-mutated human HCT116 xenografts 2007 ·Cancer Research ·Maureen E. Lane, Jeanne M. Fahey, (unknown), Nancy Hamel, Bo Yu, Brad Thompson, Matt Coffey, Scott Wadler	4
4	A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates 2004 ·Gynecologic Oncology ·Scott Wadler, Donna E. Levy, (unknown), Carla I. Falkson, (unknown), Edie Weller, Robert D. Burk, Gloria Y. F. Ho, Anna S. Kadish	39
5	Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors 2004 ·Cancer Chemotherapy and Pharmacology ·Andreas Kaubisch, (unknown), Hilda Haynes, Alla M. Rozenblit, Scott Wadler	11
6	A Phase II Study of Rebeccamycin Analog NSC 655649 in Patients with Metastatic Colorectal Cancer 2003 ·Investigational New Drugs ·Sanjay Goel, Scott Wadler, Anthony Hoffman, Fabio Volterra, Cheryl H. Baker, (unknown), Percy Ivy, (unknown), Sridhar Mani	19
7	Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 days 2002 ·Anti-Cancer Drugs ·Franco M. Muggia, Leonard Liebes, Maitreyee Hazarika, Scott Wadler, Anne Hamilton, Gila Hornreich, Joan Sorich, (unknown), Elliot Newman, M Potmĕsil, Howard S. Höchster	9
8	Phase I clinical trial of parenteral hydroxyurea in combination with pelvic and para-aortic external radiation and brachytherapy for patients with advanced squamous cell cancer of the uterine cervix 2002 ·International Journal of Radiation OncologyBiologyPhysics ·Jonathan J. Beitler, Patrick Anderson, Hilda Haynes, Brij Sood, Abbie L. Fields, Gary L. Goldberg, Bhadrasain Vikram, Carolyn D. Runowicz, Scott Wadler	8
9	Phase I-II Study of 5-Fluorouracil, Recombinant Interferon α2a, and Cisplatin in Combination With External Beam Radiation Therapy Followed by Surgery in Patients With Locally Advanced Carcinoma of the Esophagus 1999 ·American Journal of Clinical Oncology ·(unknown), Jonathan J. Beitler, Hilda Haynes, M. Camacho, Ellen L. Wolf, Scott Wadler	1
10	Carcinoma of the uterine cervix metastatic to behind the zygomatic arch: A case report 1999 ·American Journal of Otolaryngology ·(unknown), Richard V. Smith, Robin J. Mitnick, (unknown), Scott Wadler	10
11	Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. 1997 ·Journal of Clinical Oncology ·Sandra M. Swain, Fredrick S. Whaley, (unknown), Stuart P. Weisberg, Michael York, Darcy Spicer, Sarah E. Jones, Scott Wadler, Anjali Desai, Charles L. Vogel, James L. Speyer, A Mittelman, Salitha Reddy, Kelly Pendergrass, E Vélez-García, Michael S. Ewer, J. R. Bianchine, Richard A. Gams	466
12	Phase II clinical trial with 5-fluorouracil, recombinant interferon-α-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus 1996 ·Cancer ·Scott Wadler, Hilda Haynes, Jonathan J. Beitler, Xiao Hu, Stanley C. Fell, M. Camacho, Barry Levine, Peter H. Wiernik	19
13	A Phase I Trial of Cyclosphosphamide and Carboplatinum Combined with Interleukin-3 in Women with Advanced-Stage Ovarian Cancer 1995 ·Gynecologic Oncology ·James L. Speyer, John Mandeli, Howard S. Höchster, Carolyn D. Runowicz, Scott Wadler, Robert C. Wallach, Carmel J. Cohen, Dagmar Oette, Joan Sorich, Erin P. Demakos, (unknown), Gary L. Goldberg, Howard W. Bruckner, J. G. Holland	8
14	Phase II trial of chemotherapy, external and intraluminal radiation plus surgery for oesophageal cancer 1995 ·Medical Oncology ·Jonathan J. Beitler, Scott Wadler, Hilda Haynes, Stanley C. Fell, Alla M. Rozenblit, Ellen L. Wolf, Barry A. Levine	3
15	Modulation of 5-fluorouracil by interferon: a review of potential cellular targets 1995 ·Medical Oncology ·(unknown), Edward L. Schwartz, Scott Wadler	2
16	Biologic agents as biochemical modulators: pharmacologic basis for the interaction of cytotoxic chemotherapeutic drugs and interferon 1994 ·Cancer Chemotherapy and Pharmacology ·Scott Wadler, Edward L. Schwartz	7
17	Reversal of Doxorubicin Resistance by Hydrophobic, But Not Hydrophilic, Forskolins 1991 ·Molecular Pharmacology ·Scott Wadler, Chia‐Ping Huang Yang	10
18	Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. 1989 ·Journal of Clinical Oncology ·Scott Wadler, Edward L. Schwartz, Marc Goldman, (unknown), Michael Rader, Matthew Zimmerman, Loretta M. Itri, V. Weinberg, P H Wiernik	271
19	Phase II Trial of Recombinant Alpha-2b-Interferon and Low-Dose Cyclophosphamide in Advanced Melanoma and Renal Cell Carcinoma 1988 ·American Journal of Clinical Oncology ·Scott Wadler, Avi I. Einzig, Janice P. Dutcher, Niculae Ciobanu, (unknown), Peter H. Wiernik	17
20	Phase I and II Agents in Cancer Therapy: Two Cisplatin Analogues and High‐Dose Cisplatin in Hypertonic Saline or With Thiosulfate Protection 1987 ·The Journal of Clinical Pharmacology ·Joachim Z. Fuks, Scott Wadler, P H Wiernik	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact